Roche Pharma Japan
Japanese affiliate of an integrated diagnostics business focused on in vitro diagnostic reagents and instruments, clinical support, and digital solutions. Key activities include molecular and infectious-disease testing, companion diagnostics and cancer gene panels for precision oncology, cloud-based analytics and AI for clinical decision support, laboratory automation and workflow optimization, tissue-sample preparation technologies for molecular testing, and programs supporting research and professional education. The affiliate publishes policies on ethical engagement and operates transparent grant/support programs in Japan.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Automated immunoassay tumor-marker reagents and analyzers (ECLIA)
Automated immunoassay reagents and analyzers using electrochemiluminescence detection for quantitative tumor-marker measurement from small-volume specimens with short turnaround times.
High-throughput integrated clinical analyzers with modular immuno modules
Integrated analyzer systems and modular immuno-processing units designed to support multi-analyte workflows at high throughput, with features such as continuous reagent loading, extended on-board reagent stability and reduced per-test sample volume.
Automated FFPE tissue microdissection system
A specimen-preparation device that enables digital marking of target regions on FFPE slides, automated cutting and recovery using disposable chips with multiple size options, and automatic reporting of pre- and post-dissection images to improve tumor-cell content for downstream molecular testing.
Plasma-based mutation detection assays (real-time PCR)
Real-time PCR assays validated for plasma specimens to detect actionable mutations (example: EGFR) to support therapy selection and monitoring, with documented regulatory and reimbursement engagement.
Digital pathology and diagnostic data-integration platforms
Platforms for digital image management, image analysis and clinical-data aggregation to support pathology workflows and collaborative diagnostics.
Automated immunoassay tumor-marker reagents and analyzers (ECLIA)
Automated immunoassay reagents and analyzers using electrochemiluminescence detection for quantitative tumor-marker measurement from small-volume specimens with short turnaround times.
High-throughput integrated clinical analyzers with modular immuno modules
Integrated analyzer systems and modular immuno-processing units designed to support multi-analyte workflows at high throughput, with features such as continuous reagent loading, extended on-board reagent stability and reduced per-test sample volume.
Automated FFPE tissue microdissection system
A specimen-preparation device that enables digital marking of target regions on FFPE slides, automated cutting and recovery using disposable chips with multiple size options, and automatic reporting of pre- and post-dissection images to improve tumor-cell content for downstream molecular testing.
Plasma-based mutation detection assays (real-time PCR)
Real-time PCR assays validated for plasma specimens to detect actionable mutations (example: EGFR) to support therapy selection and monitoring, with documented regulatory and reimbursement engagement.
Digital pathology and diagnostic data-integration platforms
Platforms for digital image management, image analysis and clinical-data aggregation to support pathology workflows and collaborative diagnostics.
Services
Sales, installation, maintenance and customer support services for in vitro diagnostic reagents and diagnostic instruments in clinical laboratories, provided via on-site engineers and remote channels.
On-site demonstrations, user training, performance confirmation and troubleshooting performed by scientific staff to support adoption and validation of diagnostic systems and assays.
Independent support programs for academic research, professional education and public-health awareness with defined application and review processes and public transparency of awards.
Sales, installation, maintenance and customer support services for in vitro diagnostic reagents and diagnostic instruments in clinical laboratories, provided via on-site engineers and remote channels.
On-site demonstrations, user training, performance confirmation and troubleshooting performed by scientific staff to support adoption and validation of diagnostic systems and assays.
Independent support programs for academic research, professional education and public-health awareness with defined application and review processes and public transparency of awards.
Expertise Areas
- In vitro diagnostics commercialization and field support
- Molecular diagnostics and liquid biopsy PCR testing
- Companion diagnostics and oncology genomics
- Infectious disease rapid testing and serology
Key Technologies
- Real-time PCR (including plasma-based assays)
- Electrochemiluminescence immunoassay (ECLIA)
- High-throughput integrated laboratory analyzers
- Automated tissue microdissection for FFPE samples
News & Updates
Commercial release in Japan of an automated electrochemiluminescence-immunoassay reagent for SCC antigens, enabling measurement from small-volume samples with rapid turnaround (announced January 2017).
Announcement of a high-throughput immunoassay module for integrated clinical analyzers capable of increased throughput (examples up to 300 tests/hour per module), extended on-board reagent stability and reduced sample volumes (announced January 2017).
Introduction of an automated FFPE tissue-dissecting system that uses digital marking and disposable cutting chips to isolate target cell regions for downstream molecular assays (announced October 2017).
Regulatory and reimbursement decision extending insurance coverage to include plasma (real-time PCR) testing for EGFR mutations used in therapy selection prior to EGFR-TKI administration (announced December 2017).
Commercial release in Japan of a real-time PCR assay for the novel coronavirus early in the pandemic, contributing to national testing capacity and inclusion in national pathogen detection manuals.
Obtained domestic authorization for a rapid antigen test kit as an over‑the‑counter product to improve general public access to testing.
Commercial release in Japan of an automated electrochemiluminescence-immunoassay reagent for SCC antigens, enabling measurement from small-volume samples with rapid turnaround (announced January 2017).
Announcement of a high-throughput immunoassay module for integrated clinical analyzers capable of increased throughput (examples up to 300 tests/hour per module), extended on-board reagent stability and reduced sample volumes (announced January 2017).
Introduction of an automated FFPE tissue-dissecting system that uses digital marking and disposable cutting chips to isolate target cell regions for downstream molecular assays (announced October 2017).
Regulatory and reimbursement decision extending insurance coverage to include plasma (real-time PCR) testing for EGFR mutations used in therapy selection prior to EGFR-TKI administration (announced December 2017).
Commercial release in Japan of a real-time PCR assay for the novel coronavirus early in the pandemic, contributing to national testing capacity and inclusion in national pathogen detection manuals.
Obtained domestic authorization for a rapid antigen test kit as an over‑the‑counter product to improve general public access to testing.